

# CONFERENCE PROGRAM

## FRIDAY, SEPTEMBER 6

6:00 p.m.-7:40 p.m.

### WELCOME AND KEYNOTE LECTURES

America North and Center Ballroom

**Session Chair: Brian M. Wolpin**, Dana-Farber Cancer Institute, Boston, MA

6:00 p.m.-6:10 p.m.

### Welcome from Cochairs

6:10 p.m.-6:20 p.m.

### Welcome from Lead Supporters

Kerri Kaplan, Lustgarten Foundation, Woodbury, NY

Julie Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA

6:20 p.m.-7:00 p.m.

### Rising Star Keynote

#### Mechanisms and consequences of pancreatic cancer stromal evolution

Mara Sherman, Oregon Health Sciences University, Portland, OR

7:00 p.m.-7:40 p.m.

### Opening Keynote

#### Targeting innate immunity in pancreatic carcinoma

George Miller, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

7:45 p.m.-10:00 p.m.

### OPENING RECEPTION / POSTER SESSION A

American Ballroom South and Staffordshire Ballroom

## SATURDAY, SEPTEMBER 7

7:30 a.m.-8:30 a.m.

### BREAKFAST AND NETWORKING ROUNDTABLES

American Ballroom South

1. Dafna Bar-Sagi
2. Stephanie Dougan
3. Elizabeth M. Jaffee
4. Christine A. Iacobuzio-Donahue

8:30 a.m.-10:30 a.m.

### PLENARY SESSION 1: TUMOR MICROENVIRONMENT

America North and Center Ballroom

**Session Chair: Ben Z. Stanger**, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

8:30 a.m.-8:55 a.m.

### Immune contexture of primary and metastatic pancreatic cancer

Lisa Coussens, Oregon Health Sciences University, Portland, OR

8:55 a.m.-9:20 a.m.

### Regulatory T-cell depletion causes compensatory immune suppression and accelerates pancreatic carcinogenesis

Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI

9:20 a.m.-9:45 a.m.	<p><b>Heterocellular interactions in the tumor microenvironment shape tumor cell signaling</b>  Claus Jorgensen, Cancer Research UK Manchester Centre, Manchester, United Kingdom</p>
9:45 a.m.-10:00 a.m.	<p><b>Senescence induction triggers vascular remodeling and new vulnerabilities to chemo- and immunotherapy in pancreas cancer*</b>  Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, NY</p>
10:10 a.m.-10:15 a.m.	<p><b>Discussion</b></p>
<b>10:15 a.m.–10:45 a.m.</b>	<p><b>BREAK</b>  American Ballroom Foyer</p>
<b>10:45 a.m.–12:30 p.m.</b>	<p><b>PLENARY SESSION 2: GENOMICS</b>  America North and Center Ballroom</p> <p><b>Session Chair: Andrew Aguirre</b>, Dana-Farber Cancer Institute, Boston, MA</p>
10:45 a.m.-11:10 a.m.	<p><b>Clonal evolution and progression of pancreatic cancer precursor lesions</b>  Laura DeLong Wood, Johns Hopkins University, Baltimore, MD</p>
11:10 a.m.-11:35 a.m.	<p><b>Multimodal evolutionary dynamics of pancreatic cancer</b>  Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY</p>
11:35 a.m.-12:00 p.m.	<p><b>Molecular subtypes—bench to bedside</b>  Jen Jen Yeh, University of North Carolina-Chapel Hill, Chapel Hill, NC</p>
12:00 p.m.-12:15 p.m.	<p><b>Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes*</b>  Eric O'Neill, University of Oxford, Oxford, United Kingdom</p>
12:15 p.m.-12:30 p.m.	<p><b>A novel deaminase independent function of APOBEC3A catalyzes widespread chromosomal instability to drive an aggressive metastatic phenotype in pancreatic cancer*</b>  Sonja Woermann, The University of Texas MD Anderson Cancer Center, Houston, TX</p>
12:30 p.m.-12:45 p.m.	<p><b>Discussion</b></p>
<b>12:45 p.m.–3:30 p.m.</b>	<p><b>POSTER SESSION B / LUNCH</b>  Staffordshire Ballroom</p>

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

<b>3:30 p.m.–5:30 p.m.</b>	<b>PLENARY SESSION 3: IMMUNOLOGY</b> America North and Center Ballroom  <b>Session Chair: Elizabeth M. Jaffee</b> , Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
3:30 p.m.–3:55 p.m.	<b>Tumor-specific T cells reprogram mononuclear phagocytes for destruction of checkpoint blockade-resistant pancreatic cancer</b> Stephanie Dougan, Dana-Farber Cancer Institute, Boston, MA
3:55 p.m.–4:20 p.m.	<b>Immune cell signaling in human and mouse pancreas cancer</b> Aida Habtezion, Stanford University, Stanford, CA
4:20 p.m.–4:45 p.m.	<b>Targeting pancreatic cancer with TCR-engineered T cells</b> Phil Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA
4:45 p.m.–5:00 p.m.	<b>STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody*</b> Katelyn Byrne, University of Pennsylvania, Philadelphia, PA
5:00 p.m.–5:15 p.m.	<b>Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules*</b> Keisuke Yamamoto, New York University School of Medicine, New York, NY
5:15 p.m.–5:30 p.m.	<b>Discussion</b>
<b>5:30 p.m.</b>	<b>EVENING OFF / DINNER ON OWN</b>

## SUNDAY, SEPTEMBER 8

<b>7:30 a.m.–8:30 a.m.</b>	<b>BREAKFAST AND NETWORKING ROUNDTABLES</b> American Ballroom South  1. Dafna Bar-Sagi 2. Lisa Coussens 3. Brian Wolpin 4. Rosie Sears 5. Robert H. Vonderheide
<b>8:30 a.m.–10:30 a.m.</b>	<b>PLENARY SESSION 4: EARLY-STAGE TRIALS AND NOVEL TREATMENT COMBINATIONS</b> America North and Center Ballroom  <b>Session Chair: Luis A. Diaz</b> , Memorial Sloan Kettering Cancer Center, New York, NY
8:30 a.m.–8:55 a.m.	<b>CD40 immunotherapy for pancreatic cancer</b> Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

*\*Short talk from proffered abstract*

8:55 a.m.-9:20 a.m.	<b>Modulating the immune response with epigenetic agents</b> Nilofer Azad, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
9:20 a.m.-9:45 a.m.	<b>Polymerase theta synthetic lethal interaction in homologous recombination-deficient pancreatic ductal adenocarcinoma</b> Diane Simeone, New York University, New York, NY
9:45 a.m.-10:00 a.m.	<b>Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma*</b> Eileen Carpenter, University of Michigan, Ann Arbor, MI
10:00 a.m.-10:15 a.m.	<b>Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma*</b> Christine Alewine, National Cancer Institute, Bethesda, MD
10:15 a.m.-10:30 a.m.	<b>Intratumoral T-cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival*</b> Julienne Carstens, The University of Texas MD Anderson Cancer Center, Houston, TX
<b>10:30 a.m.-10:45 a.m.</b>	<b>BREAK</b> American Ballroom Foyer
<b>10:45 a.m.-12:30 p.m.</b>	<b>PLENARY SESSION 5: RAS AND ONCOGENE SIGNALING</b> America North and Center Ballroom  <b>Session Chair: Dafna Bar-Sagi</b> , New York University Langone Medical Center, New York, NY
10:45 a.m.-11:10 a.m.	<b>Deciphering the origins of PDAC development</b> Laura Attardi, Stanford University, Stanford, CA
11:10 a.m.-11:35 a.m.	<b>KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance</b> Rosalie Sears, Oregon Health Sciences University, Portland, OR
11:35 a.m.-12:00 p.m.	<b>Genomic loss of the wild-type KRAS allele in pancreatic tumor progression and metastasis</b> Gloria H. Su, Columbia University, New York, NY
12:00 p.m.-12:15 p.m.	<b>KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL*</b> Cody Rozeveld, Mayo Clinic, Rochester, MN
12:15 p.m.-12:30 p.m.	<b>Enhancing the effect of autophagy inhibition for pancreatic cancer treatment*</b> Kirsten Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC
12:30 p.m.-12:45 p.m.	<b>Discussion</b>
<b>12:45 p.m.-2:00 p.m.</b>	<b>LUNCH ON OWN</b>

*\*Short talk from proffered abstract*

# CONFERENCE PROGRAM

<b>2:00 p.m.–4:00 p.m.</b>	<b>PLENARY SESSION 6: PREVENTION AND EARLY DETECTION</b> America North and Center Ballroom  <b>Session Chair: Anirban Maitra</b> , The University of Texas MD Anderson Cancer Center, Houston, TX
2:00 p.m.–2:25 p.m.	<b>Retooling a blood-based biomarker into a theranostic agent</b> Jason Lewis, Memorial Sloan Kettering Cancer Center, New York, NY
2:25 p.m.–2:50 p.m.	<b>Early detection of pancreatic cancer—challenges and opportunities</b> Anirban Maitra
2:50 p.m.–3:15 p.m.	<b>Circulating tumor DNA in cancer diagnosis—challenges and potential</b> Anne Marie O’Broin Lennon, Johns Hopkins University, Baltimore, MD
3:15 p.m.–3:30 p.m.	<b>Evaluation of the implementation of genetic cancer screening guidelines in African-American pancreatic cancer patients in a safety net hospital*</b> Taiwo Ajose, Morehouse School of Medicine, Atlanta, GA
3:30 p.m.–3:45 p.m.	<b>The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice*</b> Dannielle Engle, Salk Institute for Biological Studies, La Jolla, CA
3:45 p.m.–4:00 p.m.	<b>Discussion</b>
<b>4:00 p.m.–6:30 p.m.</b>	<b>POSTER SESSION C / RECEPTION</b> Staffordshire Ballroom

## MONDAY, SEPTEMBER 9

<b>7:00 a.m.–8:00 a.m.</b>	<b>BREAKFAST</b> American Ballroom South
<b>8:00 a.m.–9:45 a.m.</b>	<b>PLENARY SESSION 7: METABOLISM</b> America North and Center Ballroom  <b>Session Chair: Alec Kimmelman</b> , New York University, New York, NY
8:00 a.m.–8:25 a.m.	<b>Understanding metabolic limitations in pancreatic cancer</b> Matthew Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA
8:25 a.m.–8:50 a.m.	<b>New players and unique features of cancer lysosomes</b> Rushika Perera, University of California San Francisco, San Francisco, CA
8:50 a.m.–9:15 a.m.	<b>Identifying metabolic dependencies in pancreatic cancer</b> Alec Kimmelman
9:15 a.m.–9:30 a.m.	<b>Targeting macrophage metabolism to improve therapy in pancreatic cancer*</b> Christopher Halbrook, University of Michigan, Ann Arbor, MI
9:30 a.m.–9:45 a.m.	<b>Discussion</b>

*\*Short talk from proffered abstract*

<b>9:45 a.m.-10:00 a.m.</b>	<b>BREAK</b> American Ballroom Foyer
<b>10:00 a.m.-11:45 a.m.</b>	<b>PLENARY SESSION 8: NEW MODELS SYSTEMS, ANIMALS, AND BEYOND</b> America North and Center Ballroom  <b>Session Chair: Tyler Jacks</b> , Massachusetts Institute of Technology, Cambridge, MA
10:00 a.m.-10:25 a.m.	<b>Title to be announced</b> Tyler Jacks
10:25 a.m.-10:50 a.m.	<b>Understanding and exploiting natural barriers to pancreatic tumorigenesis</b> Scott Lowe, Memorial Sloan Kettering Cancer Center, New York, NY
10:50 a.m.-11:15 a.m.	<b>Investigating the immune microenvironment in mouse models of pancreatic cancer</b> Jen P. Morton, Beatson Institute for Cancer Research, Glasgow, United Kingdom
11:15 a.m.-11:30 a.m.	<b>Preclinical models to dissect immune escape in pancreatic cancer*</b> William Freed-Pastor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA
11:30 a.m.-11:45 a.m.	<b>Assessment of tumor heterogeneity, clonal evolution, and the stromal microenvironment in metastatic pancreatic ductal adenocarcinoma and matched patient-derived organoids*</b> Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, MA
<b>11:45 a.m.-12:30 p.m.</b>	<b>CLOSING KEYNOTE</b> America North and Center Ballroom  <b>Pancreatic cancer immunotherapy: Moving forward</b> Dung Thi Le, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
<b>12:30 p.m.-12:45 p.m.</b>	<b>CLOSING REMARKS</b> America North and Center Ballroom
<b>12:45 p.m.</b>	<b>DEPARTURE</b>

*\*Short talk from proffered abstract*